Published in AIDS Weekly, September 23rd, 1996
Procept believes its PRO 2000 antiviral compound is well suited for development as a female-controlled topical product to help prevent HIV infection. Laboratory studies have shown that PRO 2000 is active against a wide range of HIV strains from both the developed and developing world.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.